胰岛素和GLP-1类似物长效化策略研究的最新进展

被引：12
|
作者：
李承业
黄文龙
钱海
机构：
[1] 中国药科大学新药研究中心
来源：
中国药科大学学报 | 2018年 / 49卷 / 06期
关键词：
胰岛素类似物; GLP-1类似物; 长效化; 糖尿病;
D O I：
暂无
中图分类号：
R91 [药物基础科学];
学科分类号：
摘要：
胰岛素类似物和胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物是糖尿病治疗领域的常用药物。胰岛素和GLP-1都属于内源性多肽,具有高效性和高选择性等优点。但传统胰岛素药物起效慢,作用时间短,且存在低血糖风险;而GLP-1因为肾脏清除和体内酶的代谢,半衰期很短,二者都不能稳定且持续地控制血糖。因此,对胰岛素和GLP-1进行长效化研究具有重要意义。本文从多肽药物长效化策略以及临床评估数据等方面出发,对已上市以及在研相关药物的研究进展进行综述,为新型长效化胰岛素和GLP-1类似物的设计提供理论参考。
引用
收藏
页码：660 / 670
页数：11
相关论文
共 47 条
  • [1] 苯硼酸类糖敏感材料在胰岛素控释系统中的应用
    李丹
    付免
    钱海
    黄文龙
    [J]. 中国药科大学学报, 2017, 48 (03) : 259 - 267
  • [2] 胰高血糖素样肽-1类似物新药的研发进展
    闫荣
    杨子义
    [J]. 中国生物制品学杂志, 2011, 24 (07) : 866 - 868+872
  • [3] Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial[J] . Richard E Pratley,Vanita R Aroda,Ildiko Lingvay,J?rg Lüdemann,Camilla Andreassen,Andrea Navarria,Adie Viljoen.The Lancet Diabetes & Endocrinology . 2018 (4)
  • [4] IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J] . N.H. Cho,J.E. Shaw,S. Karuranga,Y. Huang,J.D. da Rocha Fernandes,A.W. Ohlrogge,B. Malanda.Diabetes Research and Clinical Practice . 2018
  • [5] Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA^sub 1c^: The FREEDOM-1 HBL (High Baseline) Study[J] . Robert R Henry,Julio Rosenstock,Douglas S Denham,Prakash Prabhakar,Lise Kjems,Michelle A Baron.Diabetes Care . 2018 (3)
  • [6] LAPSInsulin115: A novel ultra-long-acting basal insulin with a unique action profile
    Wronkowitz, Nina
    Hartmann, Thorsten
    Goergens, Sven Wolfgang
    Dietze-Schroeder, Daniela
    Indrakusuma, Ira
    Choi, In Young
    Park, Sung Hee
    Lee, Young-Mi
    Kwon, Se Chang
    Kang, Yeonjoo
    Hompesch, Marcus
    Eckel, Juergen
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1722 - 1731
  • [7] How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
    Munoz-Garach, Araceli
    Molina-Vega, Maria
    Tinahones, Francisco J.
    [J]. DIABETES THERAPY, 2017, 8 (01) : 9 - 22
  • [8] A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells
    Hung Pham
    Hui, Hongxiang
    Morvaridi, Susan
    Cai, Jiena
    Zhang, Sanqi
    Tan, Jun
    Wu, Vincent
    Levin, Nancy
    Knudsen, Beatrice
    Goddard, William A., III
    Pandol, Stephen J.
    Abrol, Ravinder
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 475 (03) : 295 - 300
  • [9] A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia[J] . S. Heller,C. Mathieu,R. Kapur,M. L. Wolden,B. Zinman.Diabetic Medicine . 2016 (4)
  • [10] Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V.
    Vilsboll, T.
    Langbakke, I. H.
    Kvist, K.
    Gough, S. C. L.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 40 - 48
12345